PL352756A1 - Kombinacja inhibitorów FBPazy i uczulaczy na insulinę do leczenia cukrzycy - Google Patents

Kombinacja inhibitorów FBPazy i uczulaczy na insulinę do leczenia cukrzycy

Info

Publication number
PL352756A1
PL352756A1 PL99352756A PL35275699A PL352756A1 PL 352756 A1 PL352756 A1 PL 352756A1 PL 99352756 A PL99352756 A PL 99352756A PL 35275699 A PL35275699 A PL 35275699A PL 352756 A1 PL352756 A1 PL 352756A1
Authority
PL
Poland
Prior art keywords
diabetes
treatment
combination
insulin
insulin sensitizers
Prior art date
Application number
PL99352756A
Other languages
English (en)
Inventor
Mark D. Erion
Paul Vanpoelje
Original Assignee
Metabasis Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics, Inc. filed Critical Metabasis Therapeutics, Inc.
Publication of PL352756A1 publication Critical patent/PL352756A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PL99352756A 1998-12-24 1999-12-22 Kombinacja inhibitorów FBPazy i uczulaczy na insulinę do leczenia cukrzycy PL352756A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11471898P 1998-12-24 1998-12-24
PCT/US1999/030713 WO2000038666A2 (en) 1998-12-24 1999-12-22 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES

Publications (1)

Publication Number Publication Date
PL352756A1 true PL352756A1 (pl) 2003-09-08

Family

ID=22357016

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99352756A PL352756A1 (pl) 1998-12-24 1999-12-22 Kombinacja inhibitorów FBPazy i uczulaczy na insulinę do leczenia cukrzycy

Country Status (25)

Country Link
EP (1) EP1143955B1 (pl)
JP (1) JP2003515523A (pl)
KR (3) KR20070046210A (pl)
CN (3) CN1714866A (pl)
AT (1) ATE300288T1 (pl)
AU (1) AU771039B2 (pl)
BR (1) BR9917005A (pl)
CA (1) CA2354053A1 (pl)
CZ (1) CZ20012353A3 (pl)
DE (1) DE69926400T2 (pl)
DK (1) DK1143955T3 (pl)
ES (1) ES2246586T3 (pl)
HK (1) HK1046863B (pl)
HU (1) HUP0402506A3 (pl)
ID (1) ID30237A (pl)
IL (2) IL143569A0 (pl)
MX (1) MXPA01006511A (pl)
NO (1) NO20013115L (pl)
NZ (1) NZ512219A (pl)
PL (1) PL352756A1 (pl)
PT (1) PT1143955E (pl)
RU (2) RU2227749C2 (pl)
SK (1) SK9172001A3 (pl)
WO (1) WO2000038666A2 (pl)
ZA (1) ZA200105016B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
KR100818845B1 (ko) 1998-09-09 2008-04-01 메타베이시스 테라퓨틱스, 인크. 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
AU784370B2 (en) * 1999-12-22 2006-03-23 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
JP2003525944A (ja) 2000-03-08 2003-09-02 メタバシス・セラピューティクス・インコーポレイテッド 新規アリールフルクトース−１，６−ビスホスファターゼ阻害剤
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1372660A2 (en) * 2000-07-06 2004-01-02 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1340749A4 (en) * 2000-11-17 2007-09-05 Takeda Pharmaceutical ISOXAZOLE DERIVATIVES
EP2223927B1 (en) 2002-05-13 2014-10-15 Metabasis Therapeutics, Inc. Salts of a phosphonic acid based prodrug of PMEA
WO2003095665A2 (en) 2002-05-13 2003-11-20 Metabasis Therapeutics, Inc. Pmea and pmpa cyclic producing synthesis
AU2003264256A1 (en) * 2002-09-04 2004-03-29 Dsm Ip Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
SI1611112T1 (sl) * 2003-02-11 2012-12-31 Vernalis (R&D) Limited Izoksazolne spojine kot inhibitorji vroäśinskih ĺ ok proteinov
JP4638355B2 (ja) * 2003-12-26 2011-02-23 協和発酵キリン株式会社 チアゾール誘導体
JP2008510018A (ja) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規チアゾール阻害物質
BRPI0519006A2 (pt) * 2004-12-13 2008-12-23 Daiichi Sankyo Co Ltd uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
EP1825854A1 (en) * 2004-12-15 2007-08-29 Daiichi Sankyo Company, Limited MEDICINAL COMPOSITION CONTAINING FBPase INHIBITOR
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Combined drug for treating diabetes
EP1894930A4 (en) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US9631825B2 (en) 2012-12-18 2017-04-25 Nortek Air Solutions, Llc Air filter assembly
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CN105481896A (zh) * 2015-12-03 2016-04-13 浙江大学 一种地马格列的制备方法
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
JPH03157377A (ja) * 1988-11-18 1991-07-05 Takeda Chem Ind Ltd チオ尿素誘導体及びａｇｅ生成阻害剤
DE69014562T2 (de) * 1989-01-24 1995-06-22 Gensia Pharma Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6284748B1 (en) * 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
DE69819311T2 (de) * 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
US6054587A (en) * 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase

Also Published As

Publication number Publication date
KR100689943B1 (ko) 2007-03-08
EP1143955B1 (en) 2005-07-27
NO20013115D0 (no) 2001-06-21
ZA200105016B (en) 2002-09-19
HK1046863B (zh) 2008-07-25
AU2058300A (en) 2000-07-31
WO2000038666A3 (en) 2001-11-29
CN1350466A (zh) 2002-05-22
SK9172001A3 (en) 2002-04-04
KR20060114724A (ko) 2006-11-07
KR20010099942A (ko) 2001-11-09
DE69926400D1 (de) 2005-09-01
EP1143955A2 (en) 2001-10-17
BR9917005A (pt) 2002-04-02
CN100352505C (zh) 2007-12-05
PT1143955E (pt) 2005-11-30
MXPA01006511A (es) 2004-03-19
IL143569A (en) 2006-06-11
EP1143955A3 (en) 2002-08-28
HUP0402506A2 (hu) 2005-04-28
WO2000038666A2 (en) 2000-07-06
HK1046863A1 (zh) 2003-01-30
IL143569A0 (en) 2002-04-21
CN1714866A (zh) 2006-01-04
RU2227749C2 (ru) 2004-04-27
DK1143955T3 (da) 2005-11-14
KR20070046210A (ko) 2007-05-02
HUP0402506A3 (en) 2007-05-29
AU771039B2 (en) 2004-03-11
ES2246586T3 (es) 2006-02-16
JP2003515523A (ja) 2003-05-07
NO20013115L (no) 2001-08-24
ID30237A (id) 2001-11-15
DE69926400T2 (de) 2006-05-24
RU2003132054A (ru) 2005-04-20
NZ512219A (en) 2004-12-24
CA2354053A1 (en) 2000-07-06
CZ20012353A3 (cs) 2001-12-12
ATE300288T1 (de) 2005-08-15
CN101164618A (zh) 2008-04-23

Similar Documents

Publication Publication Date Title
IL143569A0 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
IL157821A0 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
MY169308A (en) Treatment of tnf? related disorders
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
UA85041C2 (ru) Способ лечения кишечной непроходимости
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
AU7371600A (en) Use of alpha-linolenic acid metabolites for treatment or prevention of cancer
MXPA04002572A (es) Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol.
MXPA03006631A (es) Combinaciones de secuestrante(s) de los acidos biliares y de inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
AU7564396A (en) Rac-proteine kinase as therapeutic agent or in diagnostics
IL186356A0 (en) Method of treating of preventing type-2 diabetes
AP9801261A0 (en) Farnesyl transferase inhibitors in combination with HMG COA reductase inhibitors for the treatment of cancer.
WO2003035048A3 (en) Methods for the treatment of osteoarthritis and compositions thereof
WO2005013802A3 (en) Trefoil factor 3 (tff3) as a target for anti-cancer therapy
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
NZ514691A (en) Method to type prion proteins
AU5434899A (en) Cancer treatment
AU2003282035A1 (en) Modulation of s6 kinase activity for the treatment of obestiy

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)